Going anti-Viral
Introducing Going anti-Viral, the podcast of the IAS–USA, a professional continuing medical education organization focused on HIV and other viral diseases. I’m Dr Michael Saag, professor emeritus of medicine and infectious diseases at the University of Alabama at Birmingham and volunteer member of the IAS–USA Board of Directors.
Join us as we interview experts in viral medicine about their area of specialty and current developments in the field. Other episodes are drawn from the IAS-USA vast catalogue of panel discussions, Dialogues, and various meetings and conferences.
Going anti-Viral is a podcast series for clinicians, produced by the International Antiviral Society–USA. The IAS–USA is a not-for-profit professional organization committed to improving the treatment, care, and quality of life for people with or at risk for HIV or other viral infections and their complications through balanced education and information. This podcast is intended as a clinical source of information for specialists in this field, but we hope anyone listening will enjoy learning more about the state of modern medicine around viral infections and their consequences.
Going anti-Viral
Episode 46 – Development of a Hepatitis C Cure – Dr Raymond Schinazi
In this episode of Going Anti-Viral, Dr Raymond Schinazi joins host Dr Michael Saag for an in-depth conversation about the development of a cure for hepatitis C. Dr Schinazi, the Frances Winship Walters Professor of Pediatrics and Director of the Laboratory of Biochemical Pharmacology at Emory University, shares insights from his distinguished career in antiviral research and development. He begins by outlining his background and long-standing interest in antiviral therapies, including groundbreaking work in HIV treatment. The conversation then shifts to his pivotal role in the development of sofosbuvir, a breakthrough direct-acting antiviral drug in the cure for hepatitis C, and the importance of NS5A inhibitors in antiviral drug regimens. Dr Schinazi also offers a rare behind-the-scenes look at the business and regulatory journey of bringing a transformative therapy to market, reflecting on the personal impact of this milestone. The episode concludes with a discussion of his current research into potential treatments for hepatitis B.
0:00 – Introduction
1:24 – Overview of Dr Schinazi’s background and his interest in antiviral therapy
2:56 – Discussion of Dr Schinazi’s work in the development of antiviral agents for HIV
4:45 – Background on the development of sofosbuvir for the cure of hepatitis C
10:01 – The role of NS5A inhibitors in treatment
12:42 – History of bringing hepatitis C treatment to market
14:25 – Discussion of the effectiveness of NS5A inhibitors
16:49 – The risk of reinfection and review of the basic science behind pharmaceuticals for hepatitis C
18:22 – How the discovery of a hepatitis C cure impacted Dr Schinazi personally
25:16 – Overview of Dr Schinazi’s current research in Hepatitis B
__________________________________________________
Produced by IAS-USA, Going anti–Viral is a podcast for clinicians involved in research and care in HIV, its complications, and other viral infections. This podcast is intended as a technical source of information for specialists in this field, but anyone listening will enjoy learning more about the state of modern medicine around viral infections.
Going anti-Viral’s host is Dr Michael Saag, a physician, prominent HIV researcher at the University of Alabama at Birmingham, and volunteer IAS–USA board member. In most episodes, Dr Saag interviews an expert in infectious diseases or emerging pandemics about their area of specialty and current developments in the field. Other episodes are drawn from the IAS–USA vast catalogue of panel discussions, Dialogues, and other audio from various meetings and conferences.
Email podcast@iasusa.org to send feedback, show suggestions, or questions to be answered on a later episode.
Follow Going anti-Viral on:
Apple Podcasts
YouTube
X
Facebook
Instagram
...